ivosidenib
servier
['tibsovo', 'ivosidenib', 'servier']
servier presents updated p-i study results of tibsovo (ivosidenib) for idh1-mutated relapsed/refractory myelodysplastic syndromes at eha 2023 #clinicaltrials 
Real-time summarized News in 3 shots from pharma, biotech, medtech, digital health and life sciences industry readable in 60 seconds